Estimates of overall survival according to pretreatment mutation status, B2M, and posttreatment MRD. (A) OS according to mutation status. (B) OS according to mutation status and baseline B2M. (C) Six-month landmark OS according to the achievement of posttreatment MRD-negativity. (D) Six-month landmark OS from end-of-therapy according to mutation status and the achievement of posttreatment MRD-negativity.